ICICI Securities Limited
Sun Pharma (Sun) is acquiring US-based early-stage oncology-focused biotech company Checkpoint Therapeutics (Checkpoint) for an upfront cash payment of USD 4.1/share (total outgo of USD 355mn) and USD 0.7/share in cash in future milestones.
Motilal Oswal released a Buy report for Sun Pharmaceutical Industries Ltd. with a price target of 1960.0 on 23 Sep, 2025.
More from Sun Pharmaceutical Industries Ltd.
Recommended